AAGP eNews
Apr. 7, 2015

Many doctors who diagnose Alzheimer's fail to tell the patient
Doctors are much more likely to level with patients who have cancer than patients who have Alzheimer's, according to a report released by the Alzheimer's Association. The report found that just 45 percent of Medicare patients who'd been diagnosed with Alzheimer's said they were informed of the diagnosis by their doctor. By contrast, more than 90 percent of Medicare patients with cancer said they were told by their doctor.More

A new amyloid-targeting treatment for Alzheimer's disease
News Medical
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients. Gamma secretase inhibitors tend to produce adverse effects by interacting with Notch, an important pathway for cellular signaling. More

2015 IPA International Congress
The International Psychogeriatric Association (IPA) will be holding its 2015 IPA International Congress in Berlin, Germany, Oct. 13-16, 2015. IPA is the only international, multi-disciplinary association discussing the broad needs of old age mental health — from healthy aging to the diseases of the aged (dementia, depression, agitation, capacity, and more). IPA offers meetings that are essential opportunities for collaborating with colleagues with diverse backgrounds and many interests but with a common purpose ... to improve the mental health of older people. More

What Ronald Reagan's speech patterns can reveal about Alzheimer's disease
Medical Daily via Raw Story
Toward the end of his presidency, Ronald Reagan, once famed as "The Great Communicator," began losing the luster on his oratory prowess. In November of 1994, five years out of office, doctors diagnosed him with Alzheimer's disease. A new analysis suggests the signs may have been evident even before he left the White House. The findings hail from Arizona State University and are published in the Journal of Alzheimer’s Disease. They give credence to a method of disease detection that relies on analyzing speech patterns for irregularities, such as the repetition of certain phrases or forgetting them altogether. More

Study: Cancer drug found to restore memory in mice holds promise as Alzheimer's treatment
The Washington Post
A drug originally designed to target cancer has been found to restore memory and reverse cognitive problems in mice with Alzheimer's disease-like symptoms and could offer a path forward to a treatment for humans someday, a new study found. Yale University researchers found that the previously approved drug, saracatinib, targeted beta amyloid deposits and reduced their toxic effect on surrounding brain cells. The buildup of beta amyloid in the brain can be a precursor of Alzheimer's disease in the aging brain. More

New test standard may help detect Alzheimer's disease earlier
Walter Ralston started noticing the signs of Alzheimer's in his wife Joyce seven years ago. "When she was taking her driving test, she took it three times," Walter Ralston said. Cognitive testing is one way doctors chart how well a patient is doing, but it's not definitive. Another way to diagnose is through MRI scans to see if a specific part of the brain — the hippocampus — is shrinking. Now, after six years of painstaking study, scientists at UCLA's Mary S. Easton Center for Alzheimer's Disease Research have developed the gold standard to measure the brain for that type of testing.More

Study translates genetic risk factor into Alzheimer's disease prevention strategy
Medical Xpress
What if a failed leukemia drug could reduce the risk of Alzheimer's disease? A team at the University of Kentucky recently led an effort to investigate this hypothesis. Their results were published in the journal, Human Molecular Genetics. The U.K. researchers, led by Steve Estus at the Sanders-Brown Center on Aging, study a genetic variant in a gene called CD33 that reduces the risk of Alzheimer's disease. More

Disrupted biological clock linked to Alzheimer's disease
Medical Xpress
New research has identified some of the processes by which molecules associated with neurological diseases can disrupt the biological clock, interfere with sleep and activity patterns, and set the stage for a spiral of health concerns that can include a decreased lifespan and Alzheimer's disease. The research was published in Neurobiology of Disease by scientists from Oregon State University and the Oregon Health & Science University, in work supported by the National Institutes of Health. More

Caffeine may treat or even prevent Alzheimer's disease
Science 2.0
A new study suggests a possible role for caffeine treatment Alzheimer's disease (AD) treatment, by showing a link between caffeine and reductions in the beta amyloid plaque accumulation characteristic of Alzheimer's disease. The latest evidence linking beta amyloid protein to Alzheimer's disease and exploring the relationship between caffeine and beta amyloid are featured in a review article in Journal of Caffeine Research. More